Paul Tudor Jones Adaptive Biotechnologies Corp Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 515,772 shares of ADPT stock, worth $2.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

515,772

Previous 515,384 0.08%

Holding current value

$2.42 Million

Previous $1.87 Million 41.55%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.37 - $5.12 $1,307 - $1,986	388 Added 0.08%	515,772 $2.64 Million
Q2 2024 Aug 14, 2024	BUY	$2.34 - $3.96 $1.06 Million - $1.79 Million	452,252 Added 716.36%	515,384 $1.87 Million
Q1 2024 May 15, 2024	BUY	$2.88 - $4.8 $181,820 - $303,033	63,132 New	63,132 $202,000
Q3 2022 Nov 14, 2022	BUY	$6.5 - $12.67 $873,190 - $1.7 Million	134,337 New	134,337 $956,000
Q1 2022 May 16, 2022	SELL	$10.12 - $28.9 $455,946 - $1.3 Million	-45,054 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $949,714 - $1.39 Million	37,732 Added 515.32%	45,054 $1.26 Million
Q3 2021 Nov 15, 2021	SELL	$30.02 - $39.87 $877,214 - $1.17 Million	-29,221 Reduced 79.96%	7,322 $249,000
Q2 2021 Aug 16, 2021	BUY	$32.22 - $44.59 $965,053 - $1.34 Million	29,952 Added 454.44%	36,543 $1.49 Million
Q1 2021 May 17, 2021	BUY	$37.26 - $67.74 $245,580 - $446,474	6,591 New	6,591 $265,000
Q3 2019 Nov 14, 2019	SELL	$30.31 - $53.51 $151,550 - $267,550	-5,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$40.3 - $48.3 $201,500 - $241,500	5,000 New	5,000 $242,000

Others Institutions Holding ADPT

# of Institutions

201

Shares Held

146M

Call Options Held

68.8K

Put Options Held

42.5K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $670M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account